# Arvinas (ARVN) — News

ARVN · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/arvn/news

## Recent headlines

- [Arvinas: Phase 1 ARV-102 showed dose-dependent improvements in eye movement in Parkinson's patients](https://www.ainvest.com/news/arvinas-phase-1-arv-102-showed-dose-dependent-improvements-eye-movement-parkinson-patients-2610) — AInvest Wire, Oct 7, 2026
  Arvinas Inc. (ARVN) has reported preliminary findings from its Phase 1 clinical trial of ARV-102, an investigational therapy targeting Parkinson’s disease. The data indicate dose-dependent improvements in eye movement among participants, a key biomarker associated with the condition. These results,…
- [Arvinas: Findings support evaluation of ARV-102 as a therapeutic approach for neurodegenerative diseases associated with LRRK2 dysregulation](https://www.ainvest.com/news/arvinas-findings-support-evaluation-arv-102-therapeutic-approach-neurodegenerative-diseases-lrrk2-dysregulation-2610) — AInvest Wire, Oct 7, 2026
  Arvinas, Inc. (Nasdaq: ARVN) continues to advance its pipeline of investigational therapies based on its proprietary PROTAC (PROteolysis TArgeting Chimera) platform. One of its key programs, ARV-102, is an orally bioavailable PROTAC designed to target and degrade leucine-rich repeat kinase 2…
- [Arvinas shares novel oculomotor and biomarker data from phase 1 clinical trial of ARV-102 in patients with Parkinson’s disease](https://www.ainvest.com/news/arvinas-shares-oculomotor-biomarker-data-phase-1-clinical-trial-arv-102-patients-parkinson-disease-2610) — AInvest Wire, Oct 7, 2026
  Arvinas, Inc. (Nasdaq: ARVN) announced that novel oculomotor and biomarker data from the Phase 1 clinical trial of its investigational drug ARV-102 in patients with Parkinson’s disease will be presented at the 2026 International Congress of Parkinson’s Disease and Movement Disorders (MDS) in Seoul,…
- [Arvinas announces first patient dosed in phase 1/2 clinical trial of ARV-6723, the company’s first immuno-oncology candidate](https://www.ainvest.com/news/arvinas-announces-patient-dosed-phase-1-2-clinical-trial-arv-6723-company-immuno-oncology-candidate-2609) — AInvest Wire, Sep 28, 2026
- [US FDA - Authorizes Guardant360 CDX assay as companion diagnostic for breast cancer](https://www.ainvest.com/news/fda-authorizes-guardant360-cdx-assay-companion-diagnostic-breast-cancer-2609) — AInvest Wire, Sep 4, 2026
  The U.S. Food and Drug Administration (FDA) has authorized the Guardant360® CDx liquid biopsy test as a companion diagnostic for the treatment of estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), estrogen receptor 1 (ESR1)-mutated advanced or metastatic…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).